X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Event: New era of medicine comes to Capitol Hill

By Lori Reilly  |    April 30, 2019
Biopharmaceutical researchers work every day to translate science into new treatments and cures. This passion has led to breakthroughs like gene therapy to treat childhood blindness, ...   Read More

Giving patients a voice: PhRMA launches Voters for Cures to support the next generation of treatments and cures

By Robert Zirkelbach  |    April 25, 2019
When we launched the GOBOLDLY campaign two years ago, we set out to spotlight the new era of medicine and the tremendous opportunity that exists to tackle our most complex and devastating health...   Read More

IP Explained: What they are saying on the importance of strong intellectual property protections

By Tom Wilbur  |    April 24, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections to maintain its role as the global leader in biopharmaceutical innovation. Strong and...   Read More

New report shows more than 160 medicines in development for diabetes and related conditions

By Andrew Powaleny  |    April 24, 2019
Diabetes represents a significant public health issue in the U.S. It affects more than 30 million Americans, including around 7.2 million who are undiagnosed. Additionally, there are close to 1.5...   Read More

IP Explained: Why patents are so critical to biopharmaceutical innovation

By Tom Wilbur  |    April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...   Read More

Minority health matters

By Courtney Christian  |    April 15, 2019
April is National Minority Health Month, a time to recognize and raise awareness of health disparities that affect racial and ethnic minorities.   Read More

Six policy solutions to help patients afford their insulin

By Holly Campbell  |    April 9, 2019
Dramatic improvements in how we treat diabetes have transformed the lives of patients, but too many struggle to afford their insulin and other medicines at the pharmacy counter. Due to...   Read More

PhRMA comments on OIG proposed rule to reform the rebate system

By Holly Campbell  |    April 8, 2019
Today, PhRMA submitted comments on the Department of Health & Human Services (HHS) Office of Inspector General (OIG) proposed rule, “Removal of Safe Harbor Protection for Rebates Involving...   Read More

340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings

By Nicole Longo  |    April 5, 2019
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? Evidence continues to show otherwise. An updated analysis from Berkeley Research Group (BRG) is the latest to build...   Read More

New report shows nearly 20 innovative medicines in development for sickle cell disease

By Andrew Powaleny  |    April 2, 2019
Sickle cell disease (SCD) is the most common inherited blood disorder in the United States, afflicting nearly 100,000 Americans. Patients with SCD have sickle-shaped red blood cells, which have...   Read More

Five key facts about the market for insulins

By Holly Campbell  |    April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates